Endo International PLC (NASDAQ:ENDP) – Stock analysts at Gabelli cut their FY2020 earnings estimates for shares of Endo International PLC in a research note issued to investors on Thursday. Gabelli analyst K. Kedra now anticipates that the company will post earnings of $4.00 per share for the year, down from their previous estimate of $4.20. Gabelli also issued estimates for Endo International PLC’s FY2021 earnings at $4.60 EPS.

Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings results on Tuesday, May 9th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.10 by $0.13. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter last year, the company posted $1.08 EPS. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: “Brokers Offer Predictions for Endo International PLC’s FY2020 Earnings (NASDAQ:ENDP)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/07/brokers-offer-predictions-for-endo-international-plcs-fy2020-earnings-nasdaqendp-updated-updated-updated.html.

Several other equities research analysts also recently issued reports on ENDP. Canaccord Genuity set a $14.00 target price on Endo International PLC and gave the stock a “hold” rating in a research report on Tuesday, March 14th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $15.00 price target on shares of Endo International PLC in a report on Wednesday, March 15th. JMP Securities reaffirmed an “outperform” rating and issued a $20.00 price target on shares of Endo International PLC in a report on Wednesday, March 15th. Leerink Swann reaffirmed a “market perform” rating on shares of Endo International PLC in a report on Monday, March 20th. Finally, Mizuho reaffirmed a “buy” rating and issued a $18.00 price target (up previously from $17.00) on shares of Endo International PLC in a report on Thursday, April 13th. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $16.63.

Shares of Endo International PLC (NASDAQ:ENDP) traded up 3.52% during trading on Monday, hitting $11.75. The stock had a trading volume of 4,003,327 shares. The firm’s 50 day moving average is $12.19 and its 200 day moving average is $12.47. Endo International PLC has a 1-year low of $9.70 and a 1-year high of $24.93. The company’s market cap is $2.62 billion.

Hedge funds have recently bought and sold shares of the stock. Macquarie Group Ltd. raised its stake in Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock valued at $107,000 after buying an additional 3,700 shares during the last quarter. Point View Wealth Management Inc. raised its stake in Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock valued at $128,000 after buying an additional 1,254 shares during the last quarter. Capital Fund Management S.A. acquired a new stake in Endo International PLC during the first quarter valued at about $260,000. Jensen Investment Management Inc. raised its stake in Endo International PLC by 5.8% in the first quarter. Jensen Investment Management Inc. now owns 24,660 shares of the company’s stock valued at $275,000 after buying an additional 1,360 shares during the last quarter. Finally, Advantus Capital Management Inc raised its stake in Endo International PLC by 28.8% in the first quarter. Advantus Capital Management Inc now owns 25,407 shares of the company’s stock valued at $284,000 after buying an additional 5,677 shares during the last quarter. Institutional investors and hedge funds own 93.28% of the company’s stock.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Earnings History and Estimates for Endo International PLC (NASDAQ:ENDP)

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.